Viewing Study NCT02542293

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 1:15 AM

Ignite Modification Date: 2026-01-05 @ 6:04 PM

Study NCT ID: NCT02542293

Status: ACTIVE_NOT_RECRUITING

Last Update Posted: 2025-09-16

First Post: 2015-08-26

Is NOT Gene Therapy: True

Has Adverse Events: True

Brief Title: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

Sponsor: AstraZeneca

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module Adverse Events Module Baseline Characteristics Module Participant Flow Module